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It is well established that excessive and prolonged alcohol 
use can lead to permanent damage to the structure and 
function of the brain [1]. Despite this, there is little 
consensus on the characteristics of a dementia syndrome 
related to sustained alcohol abuse or its relationship to 
Wernicke-Korsakoﬀ  syndrome (WKS). After a long 
period of neglect, research interest has increased in 
recent years and has been spurred on by clinical demand, 
increased reported rates of alcohol abuse in older people, 
and increasing alcohol consumption by women [2,3]. In 
this paper, we aim to review the neuropathology, noso-
logy, epidemiology, clinical features, and neuropsycho-
logy of alcohol-related dementia (ARD) and WKS. To 
retrieve papers for the purpose of this review, the search 
terms (alcohol OR alcoholism) AND (dementia OR brain 
damage OR brain injury OR cognitive impairment) were 
used as keywords in the Medline and PsycINFO data-
bases. Additional terms included Wernicke’s encephalo-
pathy, Korsakoﬀ , and Alcohol Amnestic Disorder. Refer-
ence lists were also scanned for relevant papers.
The controversy of alcohol-related dementia
Present diagnostic criteria for alcohol-associated cog ni-
tive disorders focus on two main syndromes of impair-
ment: WKS and ARD. ARD has enjoyed little recognition 
as a discrete clinical entity and this is due mainly to a lack 
of a distinct pathophysiological proﬁ le [4,5]. Much of the 
debate surrounding ARD encompasses whether it is 
possible to have a dementia that is the direct result of 
ethanol neurotoxicity  – a primary alcoholic dementia  – 
or whether the clinical presentation of dementia repre-
sents another underlying pathology (that is, thiamine 
deﬁ ciency) or multiple factors (for example, neurotoxicity 
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in combination with nutritional deﬁ ciencies). Attempts 
to clarify this have been hindered by confounding factors 
that often accompany the lifestyles of alcohol abusers, 
such as head injury, psychiatric and other substance 
abuse co-morbidities, and a higher rate of vascular risk 
factors [6]. In some countries, terms such as ‘alcohol-
related brain damage’ or ‘alcohol-related brain injury’ are 
preferred over ARD to reﬂ ect the heterogeneity of 
alcohol-related cognitive disorders in both etiology and 
clinical presentation [7].
The pathophysiology of alcohol-related dementia
Autopsy evaluations suggest that up to 78% of individuals 
with diagnosed alcoholism demonstrate some degree of 
brain pathology [8]. Neuroimaging and neuropathological 
evidence show prominent white matter loss (most 
notable in the prefrontal cortex, corpus callosum, and 
cerebellum) and neuronal loss in the superior frontal 
asso ciation cortex, hypothalamus, and cerebellum [1,9]. 
Th e frontal lobes of individuals with diagnosed 
alcoholism appear particularly susceptible to damage, 
with evidence of markedly decreased neuron density, 
volume shrinkage, and altered glucose metabolism and 
perfusion [10]. Partial recovery of white matter distur-
bances can occur with abstinence, and magnetic reso-
nance imaging studies indicate early reversibility of white 
matter shrinkage that is accompanied by clinical im-
prove ment in cognitive and motor abilities [11,12]. Th e 
mechanism behind recovery from white matter damage 
is thought to involve the restoration of myeli na tion and 
axonal integrity, but is vulnerable to repeated disruption 
if drinking is resumed [11]. Harper [1] concludes that the 
brain pathology of abusers of alcohol likely has two com-
po nents: one of permanent change, the other transient.
While these ﬁ ndings reﬂ ect general structural changes 
in chronic abusers of alcohol, what lesions characterize a 
clinically identiﬁ able dementia and the neuropathological 
process that underlies this process remain in dispute. Th e 
‘neurotoxicity’ hypothesis suggests that the direct physio-
logical eﬀ ects of chronic alcohol exposure can cause 
neuronal loss through glutamate excitotoxicity, oxidative 
stress, and the disruption of neurogenesis [13]. In 
particular, drinking patterns of repeated binges and with-
drawal periods may enhance neuronal injury through 
increased vulnerability of upregulated N-methyl-D-
aspar ate (NDMA) receptors to glutamate-induced excito-
toxicity. Support for the neurotoxicity hypothesis emerges 
from animal studies, which have demonstrated dose-
related ethanol-induced damage to brain struc tures  – 
including the hippocampus, hypothalamus, and cere-
bellum – that correspond with impairments in memory 
and learning [14,15]. Cholinergic neuro trans mission in 
the basal forebrain, which plays a key role in attention, 
learning, and memory, also appears to be impacted by 
prolonged intake of alcohol. Imaging studies of ‘un-
complicated alcoholics’  – individuals with no history of 
nutritional deﬁ ciency, hepatic failure, or other indirect 
forms of brain injury – conﬁ rm structural abnormalities, 
including changes to the corpus callosum, pons, and 
cerebellum [12]. However, the permanence of such 
changes, and whether they relate to neurotoxicity in 
isolation, remains to be established [1].
Another hypothesis is that thiamine (vitamin B1) 
deﬁ ciency is primarily responsible for the development of 
ARD. Individuals with alcohol use disorders are at 
particularly high risk of thiamine deﬁ ciency, not only 
from poor dietary nutrition but because alcohol directly 
compromises thiamine metabolism [16]. Th iamine 
deﬁ ciency can lead to Wernicke’s encephalopathy (WE), 
an acute neurological disorder characterized by the 
clinical triad of oculomotor abnormalities, cerebellar dys-
function, and altered mental state and by the traditionally 
deﬁ ned pathology of neuronal loss and hemorrhagic 
lesions in the paraventricular and periaqueductal grey 
matter. Not all individuals with WE show the triad of 
neurological symptoms, and the severity of signs is likely 
related to the extent of the underlying pathology [17]. To 
increase diagnostic accuracy of WE, reﬁ ned operational 
criteria specify a minimum of two symptoms for 
diagnosis, a guideline recently endorsed by the European 
Federation of Neurological Societies (EFNS) [18,19]. 
Long-term outcomes of WE can include development of 
a syndrome of profound memory impairment  – Korsa-
koﬀ  syndrome (KS)  – that appears to be related to 
additional disruption to diencephalic and hippocampal 
circuitry. As KS shares similar pathological substrates 
and often follows an episode of WE, it is commonly 
referred to as the Wernicke-Korsakoﬀ  syndrome [1]. 
Increasing evidence suggests that the WKS encompasses 
a spectrum of pathological, neurological, and cognitive 
impairments resulting from thiamine deﬁ ciency [4]. Th e 
heterogeneity in presentation of the WKS, in 
combination with a lack of distinct pathological evidence 
for ARD, has led to the suggestion that cases of ARD are 
variants of the WKS [20]. Other evidence suggests that 
ARD and WKS are distinct disorders with overlapping 
clinical symptoms and associations such as peripheral 
neuropathology and ataxia [21].
The relationship of Wernicke-Korsakoff  syndrome 
to alcohol-related dementia: pathophysiology
In cases found to have WKS pathology at autopsy, the 
syndrome was correctly diagnosed in only around 20% of 
individuals prior to death [22]. Overlap with ARD has 
been noted, and it has been hypothesized that inactive 
(chronic) WE is likely to be the main underlying 
pathology in both KS and ARD [23,24]. Individuals with 
diagnosed KS and ARD show greater loss of neurons in 
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the nucleus basalis than individuals with uncomplicated 
alcoholism, although this needs replication [25,26]. 
Graded deﬁ cits in regional brain volumes, in which 
‘uncomplicated alcoholics’ demonstrate similar but less 
severe lesions than individuals with WKS (mammillary 
bodies, thalamus, cerebellar hemispheres, and vermis), 
also suggest that subclinical bouts of thiamine deﬁ ciency 
contribute to mild structural changes in alcohol-related 
disorders [17]. In individuals with diagnosed KS, reports 
of abnormalities in brain regions beyond those associated 
with thiamine depletion also provide support for a 
‘spectrum’ of impairment in WKS that likely relates to 
damage from both thiamine and direct neurotoxicity or a 
compound eﬀ ect of both [17].
Preliminary reports from animal models suggest that 
thiamine deﬁ ciency and direct alcohol neurotoxicity 
produce similar brain eﬀ ects. Th ese include loss of cells 
in the basal forebrain, hippocampal acetylcholine hypo-
function, and shrinkage of frontal grey and white matter, 
with thiamine deﬁ ciency characterized by additional 
lesions in the diencephalon [27]. Vetreno and colleagues 
[27] suggested that the interaction between ethanol and 
thiamine deﬁ ciency does not produce more behavioral or 
neural pathology, with the exception of reduced white 
matter, than long-term thiamine deﬁ ciency alone; 
however, synergic eﬀ ects have been noted elsewhere [28]. 
Notably, pure cases of thiamine deﬁ ciency, unaccom-
panied by chronic and excessive alcohol consumption 
(such as in cases of malnutrition), show a low rate of 
progression to KS [29], giving credence to the idea that 
an interaction of causative factors is responsible for the 
lasting cognitive deﬁ cits seen in alcohol-related disorders.
How much is too much?
Th e relationship between the amount of alcohol use and 
cognitive outcomes is complicated by diﬀ ering deﬁ nitions 
of drinking levels in the literature, and this complication 
relates in part to the varying deﬁ nitions of a ‘standard 
drink’ from country to country. For example, a standard 
drink in the United Kingdom contains a relatively low 
8 grams of alcohol, compared with 10 grams in Australia, 
14 grams in the US, and 19.75 grams in Japan [30].
‘High’ levels of alcohol consumption can range from 10 
‘standard’ drinks a week [31] to more than 9  ‘standard’ 
drinks a day [32]. Reduced frontal lobe volume has been 
associated with an amount of 418 grams a week but has 
not correlated with lower levels of consumption [14]. 
One review suggested that consumption of ﬁ ve to six 
drinks per day (which, by US standards, equates to 70 to 
84 grams) over extended periods results in ‘cognitive 
ineﬃ  ciencies’, while  consumption of 10 or more standard 
drinks a day manifests as moderate cognitive deﬁ cits 
equivalent to that found in individuals with diagnosed 
alcoholism [33].
Th e diﬀ ering elements of drinking patterns (for example, 
duration and severity of abuse, binge, and withdrawal 
periods) as well as diﬃ  culties gaining an accurate self-
report of past drinking have further complicated 
attempts to link drinking levels to later cognitive impair-
ment. Estimates of past drinking habits of individuals 
diagnosed with ARD have included up to 60 years of 
drinking (and up to 120 drinks a week at heaviest), 
although there is signiﬁ cant variability in length and 
severity of drinking [34]. Oslin and colleagues [35] 
suggest ed that a ﬁ ve-year history of consuming 35 
standard drinks a week for men and 28 for women con-
stitutes a suﬃ  cient level of neurotoxic burden to risk the 
development of ARD, but this needs veriﬁ cation.
Alcohol has been examined as a risk factor for other 
dementia syndromes. Th ere are suggestions of a U- or 
J-shaped relationship between alcohol consumption and 
dementia, with low-moderate drinking levels reducing 
the risk of overall dementia but heavy use increasing the 
risk [14]. Low to moderate alcohol use is thought to 
reduce the risk of coronary artery disease and ischemic 
stroke through the inhibitory eﬀ ect of ethanol on platelet 
aggregation and reduction of inﬂ ammatory markers and 
by alteration of the serum lipid proﬁ le [36]. Th e anti-
oxidant eﬀ ect of polyphenols or ethanol itself might also 
provide neuroprotection [14]. Alternatively, heavier drink-
ing may contribute to adverse cerebrovascular changes 
(hypertension and raised triglycerides) and increased risk 
of arterial thrombosis, cardiac disorders, and strokes [6]. 
A meta-analysis examining the association of ethanol and 
incident dementia concluded that small amounts of 
alcohol likely protects against Alzheimer’s disease but 
not against vascular dementia [37]. However, others 
suggest that the beneﬁ t of moderate drinking applies to 
all forms of dementia [38]. Th is uncertainty was empha-
sized in a recent 20-year study (n = 1,300 women at least 
65 years old), which reported that moderate alcohol con-
sump tion was not protective against dementia. Further-
more, women who increased their alcohol consumption 
over the course of the study had an increased risk of 
developing dementia [39]. Interestingly, animal models 
have shown that low concentrations of alcohol protect 
cultured cortical and hippocampal neurons against the 
synapse damage induced by amyloid-β and α-synuclein, 
providing a pathological explanation for reports that 
alcohol consumption protects against the development of 
speciﬁ c dementia syndromes [40].
Nosology?
Th e current DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, 4th edition) criteria for ‘alcohol-
induced persisting dementia’ specify the persistence of 
cognitive and functional decline following cessation of 
alcohol consumption, with all other causes of dementia 
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excluded [41]. Oslin and colleagues [35] attempted to 
improve the validity and reliability of ARD diagnosis by 
standardizing alcohol consumption criteria for a 
‘probable’ diagnosis of ARD (length and severity of 
alcohol use) and specifying a minimum abstinence time 
for a dementia diagnosis to be considered. Th ese guide-
lines were not meant to be deﬁ nitive and were designed 
with the intention of stimulating further research. Even 
so, further use of their criteria has been limited to a 
handful of studies [42-44] that have inconsistently adopted 
elements of the criteria (for example, some have excluded 
participants with previous acute symptomatology of 
WKS) and diﬀ ered in participants’ ages, education level, 
and global cognitive function. Th us, current diagnostic 
criteria for ARD have been inadequately tested.
WKS is classiﬁ ed in the DSM-IV as ‘alcohol-induced 
persisting amnestic disorder’, and memory disturbance is 
the key diagnostic feature [41]. International Statistical 
Classiﬁ cation of Diseases and Related Health Problems 
(ICD-10) criteria for ‘alcohol-induced amnesic syndrome’ 
[45] are more descriptive and detail impairment of recent 
memory and disturbance of time sense in the absence of 
impaired immediate recall or generalized cognitive 
impairment.
Another term that is becoming widely used is ‘alcohol-
related brain damage’ (ARBD) (also called alcohol-related 
brain impairment), which in some countries has super-
seded the use of DSM-IV nosology [7]. Some authors do 
not encompass speciﬁ c neurological disorders that 
present with a distinct clinical and neuropathological 
presentation (for example, Marchiafava-Bignami disease) 
within this terminology [20], whereas others group these 
under the ARBD banner [7]. For many clinicians, this 
term is preferential to ARD because it better accounts for 
the heterogeneity of presentations, avoids the stigma 
associated with the term dementia, and distinguishes the 
non-progressive nature of ARD from other degenerative 
disorders. DSM-5 looks likely to adopt a similar inclusive 
approach, with plans to have categories of major and 
minor ‘neurocognitive disorder due to substance 
disorder’, which are likely to include an ‘amnestic-
confabulatory (Korsakoﬀ )’ subtype, although this is yet to 
be ﬁ nalized [46].
Prevalence of alcohol-related cognitive disorders
Given the lack of operationally deﬁ ned diagnostic 
criteria, it is not surprising that incidence and prevalence 
estimates of ARD vary in the literature. Epidemiological 
ﬁ ndings generally have been derived from population 
studies that relate patterns of alcohol consumption and 
dementia. A review by Ritchie and Villebrun [47] 
established that studies have indicated a high prevalence 
of alcohol abuse in patients with dementia (9% to 22%) 
and high rates of dementia in alcohol abusers (10% to 
24%), although most studies did not specify the type of 
dementia. Th e range in rates may be explained at least 
partially by diﬀ erences in criteria for ‘heavy’ alcohol use, 
varying age limits, and diﬀ erences in sampling. ARD 
cases generally have a younger age of onset, and 
consequently studies that exclude those under 60 years of 
age may miss a signiﬁ cant proportion of cases [47]. 
Prevalence studies of dementia subtypes in nursing 
homes have reported ARD to account for 10% to 24% of 
all dementias [43,47,48], which is likely higher than in the 
general population. Rates of ARD in dementia cases 
identiﬁ ed in neurology and memory clinics tend to be 
lower (around 3% to 5% [49,50]), which may indicate the 
lack of referrals of these patients to such clinics. Rates of 
ARD of around 10% were found in an English epidemio-
logical study of younger-onset dementia in speciﬁ c 
London districts (onset of less than 65  years) [51]. Th e 
eﬀ ect of age was demonstrated in an Australian analysis 
of hospital admissions of more than 20,000 dementia 
patients who were at least 50 years old: ARD was found 
in 1.4% of all patients with diagnosed dementia but in 
22% of dementia patients under 65 [52].
Individuals with ARD are often male, have co-morbid 
mental and physical conditions (including liver and 
digestive diseases), and are likely to be identiﬁ ed through 
hospital admissions [43,52]. Social isolation appears to be 
a signiﬁ cant factor in the poor identiﬁ cation and treat-
ment of ARD, and a high proportion of patients are 
unmarried or do not have the support of family or friends 
[43,53]. Th ese gender and social ﬁ ndings are consistent 
with reported characteristics of individuals who are 
heavy users of alcohol [2]. Th ere has been little 
examination of the prevalence of co-morbid substance 
abuse, head injuries, or psychological co-morbidities in 
the ARD popu lation despite evidence that these are 
linked to the presence and maintenance of substance use 
disorders in both younger and older adults [13,54].
Most cases of WKS in developed countries relate to the 
misuse of alcohol, although WKS syndromes following 
gastrointestinal disorders and systemic diseases can also 
contribute. While there is no direct correlation between 
the prevalence of WE and per capita consumption of 
alcohol, the introduction of thiamine supplementation 
programs in some countries, as well as general dietary 
habits, also inﬂ uences overall rates [16]. Prevalence rates 
of WKS identiﬁ ed post-mortem are thought to be 
between 1% and 2% of the general population and around 
10% of alcohol misusers in Western countries [16,19]. A 
study of KS in Th e Netherlands reported a prevalence of 
48 per 100,000 inhabitants [55], and incidence rates of KS 
in the East End of Glasgow, Scotland, were estimated at 
around 8 per 100,000 in 1995, a seven-fold increase from 
1990 [56]. A study of hospital admissions of patients at 
least 50 years old identiﬁ ed 126 cases of KS (0.05% of all 
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admissions) and 77 cases of WE (0.03% of admissions), 
although there was some overlap in diagnostic groups 
[52]. Th ere is a need for further epidemiological study of 
this population by using standardized criteria for diag-
nosis to increase accuracy in identiﬁ cation of underlying 
WKS neuropathology and allow overall prevalence rates 
to be established.
Neuropsychological fi ndings
Alcohol can have acute and chronic eﬀ ects on cognitive 
function. Direct intoxication impairs most cognitive skills 
and in excess may lead to stupor and respiratory de-
pression. Acute withdrawal in long-term alcohol abusers 
can result in tremor, hallucinations, seizures, agitation, 
and ﬂ uctuating levels of alertness [14].
Cognitive and behavioral changes speciﬁ c to ARD have 
received limited investigation. Unlike patients with other 
dementia syndromes, patients with alcohol-induced 
dementia are unlikely to demonstrate language impair-
ment, an observation incorporated into the ARD criteria 
proposed by Oslin and colleagues [21,35]; however, 
preserved confron ta tional naming has not been shown in 
all studies [44]. In comparison with individuals with 
Alzheimer’s disease, ARD groups generally performed 
better on semantic tasks (confrontational naming, cate-
gory ﬂ uency, and general knowledge) and on verbal 
memory recognition measures despite generally equiva-
lent verbal learning and overall delayed recall to 
Alzheimer’s disease groups [34,44,57]. However, the ARD 
groups had poorer performance on visuospatial measures, 
including clock drawing and copy ing tasks. Deﬁ cits on 
tasks of working memory [44], motor speed [34], and 
executive function (verbal abstract reasoning [44] and 
letter ﬂ uency [34]) have also been observed in ARD 
samples in comparison with healthy controls. While 
ﬁ ndings are limited by small samples (which in some 
cases overlapped between studies) as well as diﬀ erences 
in group characteristics (that is, global dementia 
severity), Munro and colleagues [57] proposed that the 
clinical proﬁ le of ARD reﬂ ects both cortical and 
subcortical pathology. Th is was supported by a recent 
SPECT (single-photon emission computed tomography) 
study that reported reduced regional cerebral blood ﬂ ow 
in the frontal cortices, basal ganglia, and thalami of 
patients with ARD [42].
Th e neuropsychology of WKS has been the subject of 
more extensive investigation. Patients typically demon-
strate profound anterograde amnesia and impaired recall 
of past events, with a temporally graded deﬁ cit in which 
recall is better for more remote time periods [58]. 
Implicit memory and procedural memory are compara-
tively spared. Other cognitive functions apart from 
memory may be disturbed, and impaired executive func-
tions, visuoperceptual diﬃ  culties, and disturbed working 
memory have been observed [59]. Executive deﬁ cits have 
been identiﬁ ed in 80% of patients with KS [60]. Diﬃ  -
culties are most frequently detected on tasks assessing 
higher-order organization, planning, and cognitive ﬂ exi-
bility (for example, verbal ﬂ uency and divided attention) 
[60,61]. Th ere is also evidence for variable intellectual 
function in WKS [62]. In a review of evidence for 
variability in WKS, Bowden [4] remarks that empirical 
evidence suggests that the chronic phase of WKS is more 
accurately described as ‘dementia-like deterioration’ 
rather than severe and selective amnesia.
Abstinence for as little as a week typically resolves 
many of the deﬁ cits associated with heavy alcohol con-
sumption, and further recovery of cognitive abilities can 
continue over several years. Th e pattern and rate of 
cognitive recovery are not yet fully understood; however, 
there is some suggestion that verbal deﬁ cits resolve faster 
than visuospatial diﬃ  culties [13]. Executive function, 
working memory, and perceptual and motor impairments 
commonly endure following short-term abstinence, which 
has been proposed to partly reﬂ ect compromised fronto-
cortico-cerebellar functional networks [10]. Recovery of 
cognitive skills appears to be linked to amount of recent 
alcohol use and duration of abstinence rather than life-
time alcohol consumption. Multiple withdrawals and 
binge drinking may signiﬁ cantly exacerbate cognitive 
deﬁ cits [32,63]. Older drinkers show greater alcohol-
related cognitive changes and are less likely to recover 
function once they cease drinking, even after drinking 
history is controlled for [13]. Other factors such as 
gender and education also likely contribute to vulnera-
bility to cognitive impairment, and lower levels of educa-
tion are associated with less recovery over time and 
females appear to be more vulnerable to cognitive im-
pair ment despite generally lower drinking levels than men 
[13,63]. It is unclear whether education is a protective 
factor or whether low pre-morbid intelligence is a risk for 
both cognitive impairment and poor educational attain-
ment [13]. It has also been suggested that genetic 
inﬂ uences – such as a family history of alcoholism – may 
be a risk factor for development of alcohol use cognitive 
disorders, with cognitive dysfunction potentially predat-
ing alcohol misuse [13].
Another feature common to ARD and WKS is stability, 
and even improvement, in cognitive functioning over 
time provided that abstinence is maintained. A two-year 
follow-up of nursing home residents with dementia 
reported that patients with ARD demonstrated a stabili-
zation of cognitive and functional status, as opposed to 
individuals with Alzheimer’s disease or vascular dementia 
who experienced a general decline [43]. Th is is consistent 
with reports from a Scottish study [64] of stability and 
even improvement in some cognitive domains for an 
ARD group over a one-year follow-up. Similarly, 
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indi viduals with WKS also have potential for recovery, 
although this is not commonly recognized [4]. Improve-
ments in general knowledge, visual long-term memory, 
and verbal ﬂ uency have been found in abstinent 
individuals with KS over two years, and cognitive 
improvement is associated with higher pre-morbid 
education and fewer detoxiﬁ cations in the past [65]. Early 
observations by Victor and colleagues [66] also suggest 
that a large proportion (21%) of individuals with KS can 
make a full recovery. Th ese clinical ﬁ ndings are consistent 
with current neuroimaging evidence that suggests the 
possibility of at least partial structural and functional 
recovery from alcohol-related brain damage if abstinence 
is maintained. A recent animal study reported that while 
the eﬀ ects of chronic ethanol exposure (including work-
ing memory and episodic memory impairment) can 
recover with prolonged abstinence, the deﬁ cits of 
thiamine deﬁ ciency (spatial memory impairment and in-
creased perseverative behavior) are more persistent [28].
Clinical considerations
Th e assessment and management of individuals with 
ARD and WKS entail a number of clinical issues. Firstly, 
a thorough nutritional and drinking history should be 
taken, with conﬁ rmation from an informant if possible. 
Secondly, all individuals with any evidence of chronic 
alcohol misuse and suspected of having WE should be 
treated immediately with parenteral thiamine [16]. 
Treatment with oral thiamine is ineﬀ ective because it 
does not achieve an adequate plasma concentration [67]. 
Furthermore, alcohol directly interferes with thiamine 
uptake [67]. While there is no consensus as to the 
optimum dose, frequency, route, and duration of 
thiamine treatment, the EFNS recom mends that in cases 
of suspected WE, thiamine be given in doses of 200 mg 
three times daily, preferably intravenously. Th is treatment 
should be continued until no further improvement in 
signs and symptoms is evident [19]. Th irdly, assessment 
of cognitive status should be conducted on an ongoing 
basis as this will allow any improvement, stabilization, or 
deterioration to be detected. Acute intoxication and 
withdrawal may exacerbate cognitive deﬁ cits, so assess-
ment following this period (which usually lasts no longer 
than 2 weeks) may allow a more accurate baseline to be 
established. Fourthly, key characteristics associated with 
alcohol-related cognitive disorders may assist with diﬀ er-
en tiation from neurodegenerative conditions. Th ese 
typically involve stabilization or improvement in cogni-
tion with abstinence; a cognitive proﬁ le involving execu-
tive, visuo spatial, and memory diﬃ  culties with spared 
language function; and neurological symptoms such as 
ataxia. Neuroimaging may suggest atrophy in the mam-
mil lary bodies, thalamus and cerebellum, and ventricular 
enlargement, although this may vary from case to case.
Patients with ARD and WKS have shown cognitive im-
prove ment following treatment with memantine, although 
these ﬁ ndings require replication [68,69]. Finally, these 
socially isolated patients are often hospital ized for another 
health condition and this presents an ideal opportunity for 
screening, identiﬁ cation, and intervention.
Conclusions
Th e evidence reﬂ ects signiﬁ cant commonality between 
ARD and WKS. Neuropsychological studies have largely 
attempted to diﬀ erentiate these syndromes by limiting 
individuals with more global cognitive impairment from 
WKS investigations and by excluding individuals with 
past symptoms of WKS from ARD studies. However, the 
validity of this distinction is now being brought into 
question. While attention has been given to the notion 
that ARD is likely related to underlying WKS pathology, 
it appears strange that more credence has not been given 
to whether WKS may clinically be a form of dementia, 
given that it typically entails multiple domains of 
cognitive impairment alongside functional deﬁ cits. While 
‘dementia’ in current neurological settings is typically 
used to describe a progressive disease of the brain, it 
perhaps more accurately encompasses a deterioration of 
intellectual or cognitive function that may or may not be 
progressive in nature [70]. Debate over the utility of the 
term ARD in the clinical setting ensues [4]. It remains to 
be seen whether the term ‘neurocognitive disorder’ will 
satisfactorily resolve these nosological issues, dispel some 
of the stigma associated with this illness, and bring a 
better understanding of alcohol-related cognitive disorders.
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